PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-24.71%
Negative net income growth while CRVO stands at 71.52%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
3.01%
Less D&A growth vs. CRVO's 36.72%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
9.00%
SBC growth of 9.00% while CRVO is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
715.46%
Slight usage while CRVO is negative at -86.24%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
244.38%
A yoy AP increase while CRVO is negative at -63.53%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
304.81%
Some yoy usage while CRVO is negative at -175.54%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
412.12%
Some yoy increase while CRVO is negative at -98.63%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
9.59%
Some CFO growth while CRVO is negative at -1.78%. John Neff would note a short-term liquidity lead over the competitor.
100.00%
CapEx growth of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
-4.76%
We cut debt repayment yoy while CRVO is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-85.80%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.